OSE IMMUNOTHERAPEUTICS
Last · Paris€2.10-0.034 (-1.59%)stale · yahoo · 46h ago
Market cap€51.9M24.7M sh
P/E · TTM-1.2fwd -1.8 · eps -1.69 · loss
Beta0.89vs S&P 500
Div yield0.00%annual · TTM
52w range
€2.062€6.84
Volume86.7Ksession
| Revenue | €2.6M |
|---|---|
| Operating income | €-37.5M |
| Net income | €-37.7M |
| Operating margin | -1431.3% |
| Net margin | -1439.1% |
| Return on equity | -135.8% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest ANNUAL · 2026-06-11
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Runway Low
- Rd Intensity High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -1439.1%
- Cash Runway Low — Cash runway ~0.5 years
- Rd Intensity High — R&D/Revenue 1295.6%
Upcoming earnings
5:30 PM UTC+2
Period
Sep 2026
Est. EPS
—
Est. revenue
0
Earnings transcripts
- Issuer webcast
02/09/2026 Webcast : Lusvertikimab & the IL-7R Pathway: An Expert Deep Dive into IBD September 2, 2026 – Click here for replay
OSE IMMUNOTHERAPEUTICS
- Issuer webcast
10/06/2026 Webcast : TEDOPI® (KOL event) June 10, 2026 – Click to view the replay
OSE IMMUNOTHERAPEUTICS
- Issuer webcast
28/08/2026 OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
OSE IMMUNOTHERAPEUTICS
- Issuer webcast
2026 investor education transcript
OSE IMMUNOTHERAPEUTICS
- Issuer webcast
Webcast Link
OSE
- Issuer webcast
Rediffusion de notre Webcast du 10 Juin 2026 "TEDOPI®, Most Advanced Therapeutic Cancer Vaccine"
OSE IMMUNOTHERAPEUTICS
Press & signals
- GlobeNewswire
OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update
- GlobeNewswire
OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients
- GlobeNewswire
OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags
—2026-12-31≈0
2026-10-152026-10-150